Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers

Funding was co-led by DCVC and Andreessen Horowitz (a16z)